Slotnik Capital's Investment in STAAR Surgical Amid Market Strength
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 06 Jan 26
Source: NASDAQ.COM
STAAR Surgical Co's stock price fell by 12.32% as it crossed below the 5-day SMA, reflecting a challenging trading session.
This decline comes despite Slotnik Capital's recent acquisition of 635,000 shares valued at approximately $17.06 million, indicating confidence in STAAR's future potential. The company reported a nearly 7% year-over-year increase in net sales, showcasing resilience in its market position, even as its stock price has decreased over the past year.
The strong financial performance, highlighted by improved gross margins and significant cash reserves, suggests that STAAR Surgical is well-positioned to navigate market fluctuations, although the stock's current movement reflects broader market dynamics.
Analyst Views on STAA
Wall Street analysts forecast STAA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for STAA is 30.75 USD with a low forecast of 30.75 USD and a high forecast of 30.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
0 Buy
3 Hold
0 Sell
Hold
Current: 19.150
Low
30.75
Averages
30.75
High
30.75
Current: 19.150
Low
30.75
Averages
30.75
High
30.75
About STAA
STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. The Company markets and sells its ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. Its EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company's newest offering, EVO Viva, has an extended depth of focus (EDoF) optic, which is designed to treat myopia with presbyopia (age-related loss of ability to focus). It also market and sell an ICL lens to treat hyperopia (farsightedness), called Visian ICL. It makes its ICL product offerings available in multiple models, powers and lengths, including some with toric ICL (TICL) versions to correct for astigmatism (blurred vision). The Company’s principal products are ICLs used in refractive surgery, including its EVO family of lenses.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
